News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News Zealand Pharma rakes in $1bn in funding for obesity drugs Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.
News EC clears first treatment for high-risk smouldering multiple... Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
